Abstract
Characteristics of inflammatory bowel diseases have been hypothesized to resemble those of the syndrome of intestinal ulceration induced in the rat by non-steroidal anti-inflammatory compounds. However, no systematic studies have been undertaken to examine this possibility. Therefore, we have studied the influence of some pharmacological agents, such as steroids and salicylazosulfapyridine (SAS), which are clinically useful in the treatment of inflammatory bowel diseases, and to review published data on other pharmacological approaches commonly used for the therapy of inflammatory bowel diseases that have been shown to counteract indomethacin-induced intestinal toxicity.
Orally administered SAS 100 to 800 mg/kg or dexamethasone 0.05 to 0.1 mg/kg exerted dose-related, anti-ulcer activity, with ED50 values and 95% confidence limits of 145 (95–222) mg/kg SAS and 0.184 (0.152–0.224) mg/kg dexamethasone.
Other treatments, including cholestyramine, lowresidue diets and antibiotics have also been reported to ameliorate clinical and experimental intestinal diseases.
The clinical significance of present findings has been discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
A. Robert,Cytoprotection by prostaglandins, Gastroenterology77, 761–767 (1979).
T.A. Miller andE.D. Jacobson,Gastrointestinal cytoprotection by prostaglandins, Gut20, 75–87 (1979).
J.B. Kirsner andR.G. Shorter,Recent development in ‘non-specific’ inflammatory bowel disease, New Engl. J. Med.306, 775–785 (1982).
J. Vane,The use of isolated organs for detecting active substances in the circulating blood, Br. J. Pharmac.23, 360–374 (1964).
O.J. Dunn,Multiple comparisons using rank sums, Technometrics6, 241–252 (1964).
G.W. Snedecor andW.G. Cochran,Statistical Methods, p. 209. The Iowa University Press, Ames, Iowa, 1972.
L. Saunders andR. Fleming,Mathematics and Statistics for Use in the Biological and Pharmaceutical Sciences, pp. 213–225. The Pharmaceutical Press, London 1971.
M.J. Derelanko andJ.F. Long Effect of corticosteroids on indomethacin-induced intestinal ulceration in the rat, Dig. Dis. Sci.25, 823–829 (1980).
W.F. Fang, A. Broughton andE. Jacobson,Indomethacin-induced intestinal inflammation, Dig. Dis. Sci.22, 749–760 (1977).
M.J. Derelanko andJ.F. Long,Influence of prednisolone on ethanol-induced gastric injury in the rat, Dig. Dis. Sci.27, 149–154 (1982).
T.H. Kent, R.M. Cardelli andF.W. Stamler.Small intestinal ulcers and intestinal flora in rats given indomethacin, Am. J. Path.54, 237–249 (1969).
D.A. Brodie, P.G. Cook, B.J. Bauer andG.E. Dagle,Indomethacin induced intestinal lesions in the rat, Toxic. appl. Pharmac.17, 615–624 (1970).
A.I. Jacknowitz,Ulcerative colitis and its treatment, Amer. J. Hosp. Pharm.37, 1635–1646 (1980).
D.T. Drees, T.L. Robbins andF.L. Crago,Effect of low-residue foods on indomethacin-induced intestinal lesions in rats, Toxic. appl. Pharmac.27, 194–199 (1974).
R.W. Enlow, W.B. Bias andF.E. Arnett,The spondylitis of inflammatory bowel disease. Evidence for a non-HLA linked axial arthropathy, Arthritis Rheum.23, 1359–1365 (1980).
S.G.M. Menwissen, B.J. Dekker Sheys, D. Agenent andG.H.J. Tytgat,Ankylosing spondylitis and inflammatory bowel disease. I. Prevalence of inflammatory bowel disease in patients suffering from ankylosing spondylitis, Ann. Rheum. Dis.37, 30–32 (1978).
G. Di Pasquale andP. Welaj,Ulcerogenic potential of indomethacin in arthritic and non-arthritic rats, J. Pharm. Pharmac.25, 831–832 (1973).
C.J. Sircar, C.F. Schwender andM.E. Carethers,Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis, Biochem. Pharmac.32, 170–171 (1983).
W.F. Stenson andE. Lobos,Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils, J. clin. Invest.69, 494–497 (1982).
B.J.R. Whittle,Arachidonic acid metabolites and the gastrointestinal toxicity of anti-inflammatory agents, Prostaglandins (Suppl.)21, 113–118 (1981).
P. Del Soldato, Non-steroidal-antiinflammatory drugs and their actions in the intestine: pharmacological, emotional, dietary and microbial factors. InSide-effects of Anti-inflammation Drugs, Vol. 6, pp. 89–101 (EdsK.D. Rainsford andG.P. Velo). Adv. in Inflammation Res. 1984.
D. Rachmilewitz, M. Ligumsky, A. Haimovitz andA.J. Treves,Prostanoid synthesis by cultured peripheral blood mononuclear cells in inflammatory disease of the bowel, Gastroenterology82, 637–639 (1982).
A. Robert,An intestinal disease produced experimentally by a prostaglandin deficiency, Gastroenterology69, 1045–1047 (1975).
R. Modigliani,Prostanoids in ulcerative colitis, Gastroenterology82, 819–820 (1982).
D.S. Rampton andG.E. Sladen,Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory durgs, Post. Grad. Med. J.57, 297–298 (1981).
H.A. Schwartz,Lower gastrointestinal side effects of non-steroidal anti-inflammatory drugs, J. Rheumatol.8, 952–954 (1981).
J. Controt, D. Roland andJ. Barbier,Acute perforation of colonic diverticula associated with short term indomethacin, Lancetii, 1055–1056 (1978).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Del Soldato, P., Foschi, D., Varin, L. et al. Indomethacin-induced intestinal ulcers in rats: Effects of salicylazosulfapyridine and dexamethasone. Agents and Actions 16, 393–396 (1985). https://doi.org/10.1007/BF01982878
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01982878